Ticker Details
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Inc is engaged in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases in specialty markets. Its products include SYMDEKO, ORKAMBI, and KALYDECO.
IPO Date:	July 24, 1991
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$126.01B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$2.13 | 1.80%
Avg Daily Range (30 D):	$7.11 | 1.52%
Avg Daily Range (90 D):	$6.64 | 1.45%

Institutional Daily Volume
Avg Daily Volume:	1.58M
Avg Daily Volume (30 D):	1.18M
Avg Daily Volume (90 D):	1.04M

Trade Size
Avg Trade Size (Sh.):	88
Avg Trade Size (Sh.) (30 D):	26
Avg Trade Size (Sh.) (90 D):	25

Institutional Trades
Total Institutional Trades:	30,886
Avg Institutional Trade:	$9.32M
Avg Institutional Trade (30 D):	$54.62M
Avg Institutional Trade (90 D):	$42.57M
Avg Institutional Trade Volume:	.05M
Avg Institutional Trades (Per Day):	5

Market Closing Trades
Avg Closing Trade:	$34.75M
Avg Closing Trade (30 D):	$197.47M
Avg Closing Trade (90 D):	$143.65M
Avg Closing Volume:	149.87K

News

Jul 10, 2026 @ 8:05 AM Vertex Pharmaceuticals Just Made a $10 Billion Mov... Source: Adria Cimino

Jul 8, 2026 @ 2:22 PM Vertex’s Crinetics Deal Balances Growth wit... Source: Chris Markoch

Jul 8, 2026 @ 11:28 AM BBH vs. XPH: Which Healthcare ETF Is Better for Be... Source: Sarah Sidlow

Jul 8, 2026 @ 7:28 AM Vertex Is Paying a 102% Premium to Acquire Crineti... Source: Eric Volkman

Jul 6, 2026 @ 11:35 AM CRISPR Therapeutics vs. Viking Therapeutics: Which... Source: Erin Kennedy

Financials
	TTM	Q1 2026	Q4 2025
Basic EPS	$17.01	$4.06	$4.69
Diluted EPS	$16.85	$4.02	$4.64
Revenue	$12.22B	$2.99B	$3.19B
Gross Profit	$10.54B	$2.59B	$2.72B
Net Income / Loss	$4.34B	$1.03B	$1.19B
Operating Income / Loss	$4.68B	$1.14B	$1.21B
Cost of Revenue	$1.68B	$392.8M	$466M
Net Cash Flow	$819.5M	$417.1M	$140M
PE Ratio

Splits
Aug 24, 2000	2:1